Drug Interaction Study in Healthy Subjects
(529 DDI ITZ Trial)
Trial Summary
What is the purpose of this trial?
This study is to assess the change of itraconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety, and tolerability of a single dose of icalcaprant in healthy participants.
Research Team
ABBVIE INC.
Principal Investigator
AbbVie
Eligibility Criteria
This trial is for healthy adults. Specific details about who can join are not provided, but typically participants must meet certain health standards and not be taking conflicting medications.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive oral Icalcaprant with Itraconazole for up to 8 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Icalcaprant
- Itraconazole
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbbVie
Lead Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois